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Abstract
Background: Teriparatide (recombinant human parathyroid hormone 1–34) is increasingly used for the treatment
of severe osteoporosis because it stimulates bone formation and may potentially enhance fracture healing. The
objective of this study was to investigate the effects of teriparatide versus a bisphosphonate on radiographic
outcomes in the treatment of osteoporotic vertebral compression fractures (OVCF).
Methods: A total of 98 patients undergoing non-operative treatment for recent single-level OVCF were reviewed
retrospectively. Thirty-eight patients were treated by a once-daily subcutaneous injection of 20 micrograms of
teriparatide (TPD group), whereas 60 patients received 35 mg of alendronate weekly (BP group). Except for these
medications, the same treatment protocol was applied to both groups. The radiographic assessments included union
status, vertebral kyphosis, and mid-vertebral body height. The rates of fracture site surgical intervention were also
compared between the two groups. The mean follow-up period was 27 months (median 22.5, range 2 – 75 months).
Results: Cox regression analysis showed that TPD reduced the time-to-union (adjusted relative hazard ratio: 1.86, 95%
C.I.: 1.21 – 2.83). The union rate at six months after treatment was 89% in the TPD group and 68% in the BP group; the
surgical intervention rate was significantly higher in the TPD group (p = 0.026, adjusted odds ratio: 8.15, 95% C.I.: 2.02 –
43.33). The change in local kyphosis was 4.6° in the TPD group and 3.8° in the BP group (p = 0.495, paired t-test). The
change of mid-vertebral body height was 4.4 mm in the TPD group and 3.4 mm in the BP group (p = 0.228, paired t-
test). Fracture site surgical interventions were not required in the TPD group; however, two patients in the BP group
eventually underwent surgical treatment for symptomatic non-union or vertebral collapse.
Conclusions: This retrospective study suggests that teriparatide may enhance fracture healing and improve the union
rate in OVCF.
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Background
Pharmaceutical agents play a major role in the treatment
of osteoporosis. Bisphosphonates, which inhibit osteoclast
activity and bone resorption, are the current first-line
medications for osteoporosis [1]. The robust suppression
of osteoclast activity may hinder bone remodeling and
maturation in the fracture healing process [2]. Although
this adverse effect on fracture healing might raise
concerns, such potential effects on healing have not been
clinically evidenced in a meta-analysis of prospective
randomized trials [3] and a systematic review [4].
Teriparatide (TPD, recombinant human parathyroid
hormone (PTH) 1–34), an osteogenic osteoporosis
agent, has been used increasingly for patients with
severe osteoporosis and at high risk of fractures. Inter-
mittent systemic administration of PTH induces bone
formation through stimulation of osteoblast proliferation
[5], prevention of osteoblast apoptosis [6] and increased
osteoblast activity [5, 7]. This pharmaceutical agent may
potentially enhance fracture healing.
Failure of fracture healing in osteoporotic vertebral
compression fracture (OVCF) leads to intractable back
pain associated with non-union [8, 9] and delayed
vertebral collapse, resulting in neurological deficits [10].
Percutaneous vertebral augmentation is a widely
accepted treatment option for OVCF. In particular, bal-
loon kyphoplasty (BKP) may correct vertebral body
height and local kyphotic deformity [11]. However, the
differences in pain control between patients who
received non-surgical care and kyphoplasty treatment
were diminished at 12 months because the non-surgical
group improved over time, probably as a result of frac-
ture healing [12, 13]. Differences in the eventual out-
come of patients with OVCF depend greatly on the
union status. To date, however, whether teriparatide
may enhance OVCF healing remains unclear. The
current retrospective comparative study aimed to inves-
tigate the effect of teriparatide versus bisphosphonate on
radiographic outcomes in the non-operative treatment
of OVCF and to determine whether teriparatide
enhances OVCF fracture healing.
Methods
A total of 98 patients who underwent non-operative
treatment for a single-level recent OVCF between April
2010 and March 2012 were reviewed retrospectively. In-
cluded were 12 males and 86 females with a mean age of
76.7 years (58 – 94 years). A recent OVCF was diag-
nosed using 1.5-tesla MRI when a signal change of the
affected vertebra (low signal intensity on the T1-
weighted image or high signal intensity in short inver-
sion time inversion recovery on the T2-weighted image)
was observed. The bone mineral densities of the lumbar
spine and femoral neck were measured before treatment
using dual-energy X-ray absorptiometry (DXA; Delphi
QDR System, Toyo Medic Company, Tokyo, Japan).
Osteoporosis was defined by a DXA-measured lumbar
spine or femoral neck bone mineral density below 70%
of the young adult mean (YAM) (T-score less than −2.5)
or 70-80% of YAM (T-score under −2.5 to −1.5) with a
fragility-related fracture [14]. Patients with steroid-
induced osteoporosis or those who underwent dialysis
for chronic renal failure were excluded from the current
investigation. The patients were divided into two treat-
ment groups based on the medication used: 38 patients
received teriparatide (TPD group) and 60 patients
received a bisphosphonate (BP group). Background
demographic data are listed in Table 1.
The TPD group received 20 micrograms of teriparatide
administered by subcutaneous injection once daily. In
the BP group, 35 mg of alendronate was orally adminis-
tered once a week (the therapeutic dose of alendronate,
70 mg per week in the United States and Europe, is lim-
ited to 35 mg per week in Japan). The bisphosphonate
group consisted of patients with OVCF who had been
treated with alendronate in the same manner from 2006.
The TPD group consisted of those who were treated
using teriparatide after teriparatide became available in
Japan. No patients in either group received calcium or
vitamin D supplements. Except for TPD and BP admin-
istration, the same treatment protocol was applied to
both groups. Patients were permitted to ambulate with a
custom-made plastic orthosis during the first week of
treatment. The mean follow-up period was 27 months
(median 22.5, range 2 to 75 months). Fifteen patients in
the TPD group and 10 patients in the BP group
Table 1 Demographic data for the teriparatide group versus
the bisphosphonate group
TPD (n = 38) BP (n = 60) p-value
Age (years) (mean ± SD) 75.5 ± 7.1 77.6 ± 8.0 0.205
Gender (male:female) 4:34 8:52 0.761
BMD at lumbar spine
(g/cm2) (mean ± SD)
0.709 ± 0.020 0.692 ± 0.019 0.561
BMD at femoral neck
(g/cm2) (mean ± SD)
0.520 ± 0.018 0.531 ± 0.015 0.655













*p < 0.05, TPD teriparatide group, BP bisphosphonate group, SD standard
deviation, BMD bone mineral density, GFR glomerular filtration rate, VCF
vertebral compression fracture, TL thoracolumbar spine (T11-L2), non-TL
non-thoracolumbar spine (T5-T10 or L3-L5)
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completed follow-up within 6 months because radio-
graphic union was achieved.
Union status and deformity of the fractured vertebra
were assessed radiographically. Radiographic examina-
tions were performed once a week during the first
month of treatment, once a month until the third
month, and once every three months subsequently until
union was confirmed. Assessment at six months after
treatment was based on the radiographs obtained at six
months plus/minus one month. The parameters
included union rate at six months and at the final
follow-up after treatment, vertebral kyphosis and mid-
vertebral body height. Three independent observers
assessed radiographic union (two examiners performed
the evaluations independently, and another examiner
independently assessed the cases when the conclusions
of the two observers differed). Non-union was diagnosed
by the presence of a vertebral cleft or abnormal motion
at the fractured vertebra on the flexion-extension radio-
graphs. Notwithstanding evidence of a vertebral cleft,
the presence of trabecular continuity or bridging of bone
around the cleft were regarded as radiographic union
(Fig. 1). The Kappa statistic of intraclass correlation
coefficient was 0.787 (95% confidence interval: 0.674 –
0.901). The Kappa statistic of inter-rater reliability was
0.952 (95% confidence interval: 0.887 – 1.000). The rate
of fracture site surgical intervention was also compared
between the two groups.
Age and bone mineral density were compared as
continuous variables using the unpaired t-test. Gender,
prevalence of pre-existing vertebral fracture, rate of
thoracolumbar (T11-L2) vertebral fracture, incidence of
posterior wall fracture, rate of prior bisphosphonate use,
and union status (presence or absence of radiographic
union) were analyzed as categorical data using Fisher’s
exact test. Mid-vertebral body height and kyphosis angle
were compared pre- and post-treatment using the paired
t-test. Progression of vertebral deformity was defined as
>15% loss of vertebral body height or >10° of kyphosis
progression [15]. The level of significance was defined as
a p-value of less than 0.05. Statistical analyses were per-
formed using JMP Pro 11 software (SAS Institute Inc.,
Cary, North Carolina, USA). Multivariate logistic regres-
sion analysis was used to evaluate associations between
union status and demographic data including pharma-
ceutical agents. Multiple dichotomous variables included
1) age (<80 or ≥80 years), 2) gender (male or female), 3)
lumbar spine bone mineral density (≤ − 2.5 or > −2.5
SD), 4) fracture level (thoracolumbar (T11-L2) or non-
thoracolumbar (T5-T10 or L3-L5)), 5) presence of pre-
existing vertebral fracture (existent or non-existent), 6)
incidence of posterior wall fracture (injured or not in-
jured), 7) rate of past bisphosphonate use (used or not
used), and 8) pharmaceutical agent (TPD or BP).
Kaplan-Meier analysis was used to compare the time-to-
union between the TPD and BP groups, and Cox regres-
sion analysis was used to examine the covariates for
time-to-union.
Results
Kaplan-Meier survival analysis showed a significant dif-
ference in the time-to-union between the two groups (p
< 0.001, log-rank test) (Fig. 2). Cox regression analysis
showed an adjusted relative hazard for TPD versus BP
use of 1.86 (95% C.I.: 1.21–2.83). The radiographic union
rate was 89% (34/38 patients) in the TPD group versus
68% (41/60 patients) in the BP group at six months after
treatment, and the difference was significant (p = 0.026,
Fisher’s exact test). At the final follow-up, 97% of
patients (37/38 patients) in the TPD group and 90% of
patients (54/60 patients) in the BP group achieved radio-
graphic union (p = 0.243, Fisher’s exact test). Multiple lo-
gistic regression analyses were conducted using stepwise
regression to adjust for heterogeneity (age, gender,
Fig. 1 Bridging bone around a vertebral cleft. Although a vertebral cleft was observed, the presence of bony bridging around the fractured
vertebra (arrows) was interpreted as diagnostic of radiographic union
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fracture level, bone mineral density, pre-existing verte-
bral fracture, medication used, posterior wall fracture,
and prior bisphosphonate use) between the two groups
(Table 2). Regarding TPD versus BP use, the adjusted
odds ratio for union at six months after treatment was
8.15 (95% C.I.: 2.02–43.33). Fracture site surgical inter-
ventions were not required in the TPD group, whereas
two patients in the BP group eventually underwent sur-
gical treatment. One patient was treated by balloon
kyphoplasty for symptomatic non-union, and the other
underwent posterior decompression and fusion for
vertebral collapse with a neurological deficit.
The change of mid-vertebral body height was 4.4 mm
in the TPD group and 3.4 mm in the BP group (p =
0.228, paired t-test) (Fig. 4). The change of local kyphosis
was 4.6° in the TPD group and 3.8° in the BP group (p =
0.495, paired t-test) (Fig. 3). Progression of vertebral
deformity (>15% loss of vertebral body height or >10° of
kyphosis progression) was observed in 66% of the TPD
group (25/38 patients) versus 60% of the BP group (36/60
patients), a difference that was not significant (p = 0.670,
Fisher’s exact test). The union rate was 84% (21/25) in the
TPD group, and 61% (22/36) in the BP group (p = 0.086,
Fisher’s exact test). Multivariate logistic regression analysis
using the stepwise method showed that teriparatide sig-
nificantly was associated with an increased union rate; the
adjusted odds ratio was 7.80 (95% C.I.: 1.41–70.35) in
cases with vertebral deformity progression.
Union at six months was achieved in 61% (11/18 pa-
tients) of those with prior bisphosphonate use (past-BP)
and in 71% (30/42 patients) of those without prior BP
use in the BP group (p = 0.547, Fisher’s exact test). The
union rate was 86% (18/21 patients) among those with
prior BP use and 94% (16/17 patients) among those
without prior BP use in the TPD group (p = 0.613, Fish-
er’s exact test). The union rate at final follow-up was
89% (16/18 patients) among those with prior BP use and
90% (38/42 patients) among those without prior BP use
in the BP group (p = 1.000, Fisher’s exact test). Union
Fig. 2 Kaplan-Meier curves for time-to-union in the TPD group versus the BP group. The Kaplan-Meier curve showed the time course of union in
the TPD group and the BP group (p < 0.001, log-rank test). The thin black arrow shows the end of follow-up with non-union, and the bold white
arrow indicates the end of follow-up due to surgical intervention. The union rate was 89% in the TPD group and 68% in the BP group by six
months after treatment (p = 0.026, Fisher’s exact test). At the final follow-up, 97% of those in the TPD group and 90% of those in the BP group
achieved a stable union (p = 0.243, Fisher’s exact test)
Table 2 Multivariable logistic regression analysis using stepwise
method for union status at 6 months after treatment
Factors p-value Adjusted odds ratio (95% CI)
Age (<80 vs. ≥80 years) 0.205 2.21 (0.65 – 8.11)
Gender p > 0.25
Fracture level (TL vs. non-TL) 0.001* 11.67 (2.48 – 83.17)
BMD at lumbar spine
(≤ − 2.5 vs. > − 2.5 SD)
0.001* 11.68 (2.48 – 83.17)
Pre-existing VCF p > 0.25
Posterior wall fracture 0.001* 8.53 (2.25 – 42.23)
Past bisphosphonate use 0.019* 4.86 (1.29 – 22.09)
Pharmaceutical agents
(TPD vs. BP)
0.002* 8.15 (2.02 – 43.33)
*p < 0.05, 95% CI 95% confidence interval, BMD bone mineral density, SD
standard deviation, VCF vertebral compression fracture, TL thoracolumbar
spine (T11-L2), non-TL non-thoracolumbar spine (T5-T10 or L3-L5), TPD
teriparatide, BP bisphosphonatecme
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occurred in 95% (20/21 patients) of those with prior BP
use and in 100% (17/17 patients) of those without prior
BP use in the TPD group (p = 1.000, Fisher’s exact test).
Time-to-union significantly differed between the TPD
group without prior BP use (3.4 ± 1.8 months) and the
BP group without prior BP use (7.7 ± 1.1 months) (p =
0.042, t-test). Whereas prior bisphosphonate use tended
to delay the time-to-union in the TPD group (3.4 ± 0.6
to 4.8 ± 0.5 months) (p = 0.070, t-test), it did not affect
the time-to-union in the BP group (7.8 ± 1.4 to 8.3 ±
2.1 months) (p = 0.827) (Table 3). The duration of prior-
BP use did not show a correlation with the OVCF time-
to-union (Fig. 4).
Discussion
The current study demonstrated that the radiographic
union rate by six months after treatment was signifi-
cantly higher in the teriparatide group (89%) than in the
bisphosphonate group (68%), with an adjusted odds ratio
of 8.15 (95% C.I.: 2.02–43.33). The time-to-union was
significantly less in the teriparatide group (p < 0.001, log-
rank test). The adjusted relative hazard for TPD versus
BP use was 1.78 (95% C.I.: 1.16–2.71). Thus, teriparatide
had the advantage of achieving a significantly higher
union rate at six months, and of achieving union earlier
in the OVCF delayed union stage. Although teriparatide
did not contribute to preventing the progression of ver-
tebral deformity, it had the advantage of achieving
union, including in cases with vertebral deformity pro-
gression (adjusted odds ratio: 7.80, 95% C.I.: 1.41–70.35).
Fig. 3 Mid-vertebral body height and vertebral kyphosis angle. Vertebral body height was 17.4 ± 0.7 mm in the TPD group and 16.6 ± 0.9 mm in
the BP group before treatment. This measure decreased to 13.0 ± 0.7 mm and 13.2 ± 0.9 mm at the final follow-up, respectively (p = 0.228, paired
t-test). The vertebral kyphosis angle was 8.6 ± 1.0° in the TPD group and 10.8 ± 0.8° in the BP group before treatment. This angle increased to
13.2 ± 1.3° and 14.6 ± 1.0° at the final follow-up, respectively (p = 0.495, paired t-test)
Table 3 Effect of bisphosphonate use prior to osteoporotic
vertebral fracture




61.0% (11/18) 71.4% (30/42) 0.547
Union rate at final
follow-up
88.9% (16/18) 90.5% (38/42) 1.000
Time-to-union
(months)
8.3 ± 2.1 7.8 ± 1.4 0.827




85.7% (18/21) 94.1% (16/17) 0.613
Union rate at final
follow-up
95.2% (20/21) 100% (17/17) 1.000
Time-to-union
(months)
4.8 ± 0.5 3.4 ± 0.6 0.070









*p < 0.05, With prior BP: with bisphosphonate use prior to the time of
osteoporotic vertebral fracture, Without prior BP: without bisphosphonate use
prior to the time of osteoporotic vertebral fracture
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This higher union rate despite the progression of verte-
bral deformity suggests that teriparatide use may help
reduce the need for surgical intervention for OVCF.
Previous randomized controlled trials demonstrated
that teriparatide accelerated fracture healing. Aspenberg
et al. conducted a prospective, randomized, double-blind
study of 102 postmenopausal women with distal radius
fractures, and showed that the time to cortical bridging
was significantly shorter in the once-daily 20-microgram
teriparatide group than in the placebo control group
[16]. Peichl et al. also demonstrated in their randomized
controlled trial of 65 patients with osteoporotic pubic
bone fractures that a once-daily injection of PTH 1–84
accelerated healing compared with treatment with vita-
min D with calcium [17]. Additionally, several clinical
cases were reported to show successful repair of non-
union in sternum fractures [18] and dens fractures [19].
According to population-based epidemiologic studies,
the prevalence of postmenopausal osteoporosis is ap-
proximately 30 to 45% in women aged 70 years [20, 21]
and 40–45% in those aged 80 years [21, 22]. Osteopor-
otic fractures and related problems impact the quality of
life in the older adult population. Failure of fracture
healing in OVCF leads to intractable back pain associ-
ated with non-union [8, 9]. Patients with symptomatic
vertebral non-union frequently require surgical interven-
tions, including balloon kyphoplasty or spinal recon-
struction. Furthermore, once non-union advances to
osteonecrosis, the collapsed vertebrae cause a progres-
sive kyphotic deformity and severe neural tissue com-
pression with neurological deficits [8, 9, 23]. These
pathologies can be managed only through major spinal
reconstruction using instrumentation [24, 25]. Thus, the
utmost priority in the treatment of OVCF is to prevent
vertebral non-union and osteonecrosis.
In the current study, the risk factors for non-union
were thoracolumbar fracture, decreased bone mineral
density, posterior wall fracture, and prior bisphospho-
nate use. Vertebral non-union typically has been
reported to occur mainly in the thoracolumbar zone
[9, 13]. This phenomenon occurs due to the high
stresses in this region generated by the transition from
the rigid thoracic spine to the flexible lumbar spine
along with the anterior element force transmission from
the kyphotic thoracic spine to the relatively neutral
thoracolumbar junction. Bone mineral density was nega-
tively correlated with the intravertebral vacuum occur-
rence rate [26, 27]. Posterior wall fracture was reported
to be a risk factor for progression of vertebral collapse
[15, 28]. These factors might be considered related to
the vulnerability of the small blood-supplying arteries in
the vertebral bodies. Interruption of the blood supply
and insufficient bone marrow neovascularization are the
likely causes of avascular necrosis of the vertebral body,
which may result in vertebral non-union [10, 13, 29].
Once vertebral necrosis occurs, union is difficult to
achieve in the presence of a vertebral cleft. Peripheral
bridging bone formation around an OVCF with vertebral
clefting was often observed using teriparatide, as shown
in Fig. 1. With peripheral bridging bone cross-linkage
along the vertebral edges, the stability of the collapsed
vertebra was recovered. Teriparatide was reported to
Fig. 4 Duration of prior bisphosphonate use and time-to-union of osteoporotic vertebral fracture. This graph showed the relationship between
the duration of bisphosphonate use at the time of OVCF and the OVCF time-to-union. The white round mark indicates the TPD group and the
black round mark indicates the BP group. The duration of bisphosphonate use did not correlate with OVCF time-to-union in either group
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promote ossification of the spinal ligaments [30] and to
accelerate hyperplastic bone formation around vertebral
fractures in a case of diffuse idiopathic skeletal hyperos-
tosis [31]. In the current study, teriparatide significantly
affected union in cases of vertebral deformity progres-
sion (adjusted odds ratio 7.80). Moreover, prior bis-
phosphonate use was an independent risk factor for
non-union at six months. The substantial suppression
of osteoclast activity with BP use might be implicated
in the current results. Prior bisphosphonate use was
associated with delayed union, particularly with teri-
paratide use. However, the duration of prior bisphos-
phonate use did not correlate with the time-to-union
and the union rate of OVCF at the final follow-up.
An explanation for this finding might be that bone
metabolism after introducing the bisphosphonate may
subside to a constant value by three months, with
maintenance of that rate thereafter. Nenonen showed
a rapid decrease and persistent change of bone meta-
bolic markers after introducing a bisphosphonate [32].
Once the metabolism was suppressed by the bisphos-
phonate, bone formation would not ensue with the
use of teriparatide.
Both the teriparatide and bisphosphonate groups were
similar regarding the inhibition of vertebral deformity
progression. Fractured vertebrae require several months
to achieve adequate mechanical strength and a stable
union. Angular kyphosis develops within several weeks
or months after injury [33, 34]. Although teriparatide
has the potential to increase bone mineral density and
vertebral body strength [35, 36], vertebral deformity
might progress before the medication has elicited its
effects on vertebral mechanical strength.
Several limitations of the current study should be
addressed. This is a retrospective comparative study that
included different sample sizes and demographics
between the two treatment groups. The inter-group dif-
ference in the ratio of prior bisphosphonate use was a
potential source of selection bias in this study. To adjust
for heterogeneity between the two treatment groups, we
used multiple logistic regression analysis. The biological
aspects of fracture healing should be examined prospect-
ively using bone metabolic markers, vitamin D, and
parathyroid hormone level status to determine whether
the state of bone turnover was comparable between the
TPD group and the BP group at baseline and to probe
whether treatment affected bone turnover in these
patients. Due to the nature of retrospective investigation,
serum bone markers could be collected only in a very
limited number of patients. In this retrospective study,
the follow-up duration after three months following
treatment differed for each doctor. Considering the
follow-up duration differences, we showed the union
rate on the Kaplan-Meier survival curve as the time
course of vertebral union for each medication. An MRI
study might help assess the early phase of fracture
healing.
Conclusions
This retrospective study suggests that teriparatide may
potentially enhance fracture healing and improve the
union rate in OVCF.
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